In order to illustrate the potential of the selected putative targets in the treatment of hormone-refractory disease, the efficacy of AIM1, ERGIC1, TMED3, and TPX2 silencing in the inhibition of prostate cancer cells cultured in androgen deprived conditions was studied. This evidence concerns the gene ERGIC1 and prostate cancer.